ReviR Therapeutics Receives Strategic Investment from CureCMT to Advance a First-of-its-Kind Precision Medicine Platform for CMT

An isogenic iPSC and AI-enabled disease modeling platform spanning multiple genetically defined CMT subtypes will be established to support patient stratification, accelerate RTX-117 development, and create a shared foundation for next-generation therapies BRISBANE, Calif., April 21, 2026...